Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
US5273992A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 2, 1992 |
| Grant date | Dec 28, 1993 |
| Priority date | — |
| Expiry date | Nov 2, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/415
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a chemical class of active compounds to be used as efficacious drugs in the treatment of sickle cell disease. The active compounds include imidazole derivatives, nitroimidazole derivatives, and triazole derivatives. These compounds are to be administered by any preferred route of administration including oral, intramuscular, intravenous, and any other parenteral route. If desired, these drugs may also be administered transmucosally, or subcutaneously, or using a dermal patch on the skin. In addition, the methodology is effective for both long term and short term therapy; may be employed prophylactically and/or therapeutically; and may be used in emergency, acute crisis clinical situations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.